세계의 암 악액질 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2033년)

Global Cancer Cachexia Market size is anticipated to grow from USD 2.9 Billion in 2024 to USD 4.62 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 5.34% during the forecast period of 2026 to 2033.

The cancer cachexia market is poised for significant growth, driven by the increasing prevalence of cancer and the rising awareness of cachexia as a serious complication associated with the disease. Cancer cachexia is a multifactorial syndrome characterized by severe weight loss, muscle wasting, and a decline in overall health, significantly impacting patients' quality of life and treatment outcomes. As healthcare providers and researchers recognize the importance of addressing cachexia in cancer care, the demand for effective therapies and management strategies is expected to rise, positioning this market for robust expansion. Current treatment options include nutritional interventions, pharmacological agents, and supportive care measures aimed at improving appetite and muscle mass.

Moreover, advancements in research and understanding of the underlying mechanisms of cancer cachexia are driving innovation within the market. The identification of specific biomarkers and pathways involved in cachexia is paving the way for the development of targeted therapies that can more effectively address this condition. For instance, the exploration of anti-inflammatory agents and anabolic steroids is gaining traction as potential treatment options. As research continues to uncover new insights into the biology of cachexia, the market is likely to expand further, driven by the promise of improved patient outcomes and quality of life.

Additionally, the growing emphasis on multidisciplinary approaches to cancer care is shaping the cancer cachexia landscape. As healthcare providers increasingly recognize the importance of integrating nutritional support, physical therapy, and psychological care into cancer treatment plans, the demand for comprehensive cachexia management solutions is likely to increase. This trend is particularly relevant in the context of personalized medicine, where tailored interventions can significantly enhance the effectiveness of cancer therapies. As the cancer cachexia market continues to evolve, the combination of innovative treatment options, a focus on holistic patient care, and ongoing research will play a crucial role in driving its future growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Therapeutics

• Progestogens
• Corticosteroids
• Combination Therapies
• Others

By Mechanism of Action

• Appetite Stimulators
• Weight Loss Stabilizers
• Others

By Distribution Channel

• Hospital Stores
• Retail Pharmacy Stores
• Online Pharmacies
• COMPANIES PROFILED
• Aeterna Zentaris Inc.
• Alder BioPharmaceuticals Inc.
• Aphios Corporation
• Eli Lilly and Company
• GTxInc.
• Helsinn Group
• Merck & Co. Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• XBiotech Inc.
• The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. CANCER CACHEXIA INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porters Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Therapeutics
  • 3.7.2 Market Attractiveness Analysis By Mechanism of Action
  • 3.7.3 Market Attractiveness Analysis By Distribution Channel
  • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL CANCER CACHEXIA MARKET ANALYSIS BY THERAPEUTICS

• 5.1. Overview By Therapeutics
• 5.2. Historical and Forecast Data Analysis By Therapeutics
• 5.3. Progestogens Historic and Forecast Sales By Regions
• 5.4. Corticosteroids Historic and Forecast Sales By Regions
• 5.5. Combination Therapies Historic and Forecast Sales By Regions
• 5.6. Others Historic and Forecast Sales By Regions

6. GLOBAL CANCER CACHEXIA MARKET ANALYSIS BY MECHANISM OF ACTION

• 6.1. Overview By Mechanism of Action
• 6.2. Historical and Forecast Data Analysis By Mechanism of Action
• 6.3. Appetite Stimulators Historic and Forecast Sales By Regions
• 6.4. Weight Loss Stabilizers Historic and Forecast Sales By Regions
• 6.5. Others Historic and Forecast Sales By Regions

7. GLOBAL CANCER CACHEXIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 7.1. Overview By Distribution Channel
• 7.2. Historical and Forecast Data Analysis By Distribution Channel
• 7.3. Hospital Stores Historic and Forecast Sales By Regions
• 7.4. Retail Pharmacy Stores Historic and Forecast Sales By Regions
• 7.5. Online Pharmacies Historic and Forecast Sales By Regions

8. GLOBAL CANCER CACHEXIA MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2 North America By Segment Sales Analysis
  • 8.3.3 North America By Country Sales Analysis
  • 8.3.4 United States Sales Analysis
  • 8.3.5 Canada Sales Analysis
  • 8.3.6 Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2 Europe By Segment Sales Analysis
  • 8.4.3 Europe By Country Sales Analysis
  • 8.4.4 United Kingdom Sales Analysis
  • 8.4.5 France Sales Analysis
  • 8.4.6 Germany Sales Analysis
  • 8.4.7 Italy Sales Analysis
  • 8.4.8 Russia Sales Analysis
  • 8.4.9 Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2 Asia Pacific By Segment Sales Analysis
  • 8.5.3 Asia Pacific By Country Sales Analysis
  • 8.5.4 China Sales Analysis
  • 8.5.5 India Sales Analysis
  • 8.5.6 Japan Sales Analysis
  • 8.5.7 South Korea Sales Analysis
  • 8.5.8 Australia Sales Analysis
  • 8.5.9 South East Asia Sales Analysis
  • 8.5.10 Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2 Latin America By Segment Sales Analysis
  • 8.6.3 Latin America By Country Sales Analysis
  • 8.6.4 Brazil Sales Analysis
  • 8.6.5 Argentina Sales Analysis
  • 8.6.6 Peru Sales Analysis
  • 8.6.7 Chile Sales Analysis
  • 8.6.8 Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2 Middle East & Africa By Segment Sales Analysis
  • 8.7.3 Middle East & Africa By Country Sales Analysis
  • 8.7.4 Saudi Arabia Sales Analysis
  • 8.7.5 UAE Sales Analysis
  • 8.7.6 Israel Sales Analysis
  • 8.7.7 South Africa Sales Analysis
  • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE CANCER CACHEXIA COMPANIES

• 9.1. Cancer Cachexia Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10. COMPANY PROFILES OF CANCER CACHEXIA INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Aeterna Zentaris Inc.
  • 10.3.1 Company Overview
  • 10.3.2 Company Revenue
  • 10.3.3 Products
  • 10.3.4 Recent Developments
• 10.4. Alder BioPharmaceuticals Inc.
  • 10.4.1 Company Overview
  • 10.4.2 Company Revenue
  • 10.4.3 Products
  • 10.4.4 Recent Developments
• 10.5. Aphios Corporation
  • 10.5.1 Company Overview
  • 10.5.2 Company Revenue
  • 10.5.3 Products
  • 10.5.4 Recent Developments
• 10.6. Eli Lilly And Company
  • 10.6.1 Company Overview
  • 10.6.2 Company Revenue
  • 10.6.3 Products
  • 10.6.4 Recent Developments
• 10.7. GTxInc.
  • 10.7.1 Company Overview
  • 10.7.2 Company Revenue
  • 10.7.3 Products
  • 10.7.4 Recent Developments
• 10.8. Helsinn Group
  • 10.8.1 Company Overview
  • 10.8.2 Company Revenue
  • 10.8.3 Products
  • 10.8.4 Recent Developments
• 10.9. Merck & Co. Inc.
  • 10.9.1 Company Overview
  • 10.9.2 Company Revenue
  • 10.9.3 Products
  • 10.9.4 Recent Developments
• 10.10. Novartis AG
  • 10.10.1 Company Overview
  • 10.10.2 Company Revenue
  • 10.10.3 Products
  • 10.10.4 Recent Developments
• 10.11. Bristol-Myers Squibb Company
  • 10.11.1 Company Overview
  • 10.11.2 Company Revenue
  • 10.11.3 Products
  • 10.11.4 Recent Developments
• 10.12. XBiotech Inc
  • 10.12.1 Company Overview
  • 10.12.2 Company Revenue
  • 10.12.3 Products
  • 10.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies